PTGS2 and ovarian carcinoma: In 2003, Denkert and colleagues performed an in vitro study to investigate the therapeutic inhibition effect between COX-isoform-specific siRNA and COX-2 selective drug NS-398 in the human ovarian carcinoma cell line (OVCAR-3) [28].